Y Intercept Hong Kong Ltd Purchases New Holdings in Harmony Biosciences Holdings, Inc. $HRMY

Y Intercept Hong Kong Ltd acquired a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) in the second quarter, Holdings Channel reports. The firm acquired 49,454 shares of the company’s stock, valued at approximately $1,563,000.

Several other large investors also recently added to or reduced their stakes in the company. Brooklyn Investment Group lifted its holdings in shares of Harmony Biosciences by 1,031.9% in the first quarter. Brooklyn Investment Group now owns 1,064 shares of the company’s stock valued at $35,000 after purchasing an additional 970 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Harmony Biosciences during the first quarter valued at $57,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Harmony Biosciences by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,218 shares of the company’s stock worth $70,000 after acquiring an additional 299 shares in the last quarter. CWM LLC boosted its position in Harmony Biosciences by 34.8% during the 1st quarter. CWM LLC now owns 2,704 shares of the company’s stock worth $90,000 after acquiring an additional 698 shares during the period. Finally, GAMMA Investing LLC grew its stake in Harmony Biosciences by 222.9% during the 1st quarter. GAMMA Investing LLC now owns 2,929 shares of the company’s stock valued at $97,000 after acquiring an additional 2,022 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Harmony Biosciences Stock Performance

Shares of HRMY opened at $28.57 on Friday. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 9.22, a price-to-earnings-growth ratio of 0.34 and a beta of 0.79. The company’s fifty day moving average is $30.68 and its 200-day moving average is $32.64. The company has a quick ratio of 3.80, a current ratio of 3.84 and a debt-to-equity ratio of 0.20. Harmony Biosciences Holdings, Inc. has a 12 month low of $25.52 and a 12 month high of $40.93.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($0.10). The business had revenue of $200.49 million during the quarter, compared to analyst estimates of $204.37 million. Harmony Biosciences had a net margin of 23.44% and a return on equity of 26.34%. The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.05 EPS. Harmony Biosciences has set its FY 2025 guidance at EPS. Equities analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Needham & Company LLC reduced their price target on shares of Harmony Biosciences from $48.00 to $41.00 and set a “buy” rating for the company in a research report on Wednesday, September 24th. UBS Group cut their target price on shares of Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. Truist Financial started coverage on shares of Harmony Biosciences in a report on Monday, July 21st. They set a “buy” rating and a $48.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Harmony Biosciences in a research note on Tuesday, October 14th. Finally, The Goldman Sachs Group assumed coverage on Harmony Biosciences in a research report on Thursday, July 10th. They set a “neutral” rating and a $33.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $44.13.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.